metformin has been researched along with Dysplastic Nevus Syndrome, Hereditary in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin use has been associated with improved survival in patients with different types of cancer, but research regarding the effect of metformin on cutaneous melanoma (CM) survival is sparse and inconclusive." | 8.31 | Association of metformin use and survival in patients with cutaneous melanoma and diabetes. ( Andersson, TML; Eriksson, H; Girnita, A; Häbel, H; Ingvar, C; Krakowski, I; Nielsen, K; Smedby, KE, 2023) |
| "Metformin use has been associated with improved survival in patients with different types of cancer, but research regarding the effect of metformin on cutaneous melanoma (CM) survival is sparse and inconclusive." | 4.31 | Association of metformin use and survival in patients with cutaneous melanoma and diabetes. ( Andersson, TML; Eriksson, H; Girnita, A; Häbel, H; Ingvar, C; Krakowski, I; Nielsen, K; Smedby, KE, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krakowski, I | 1 |
| Häbel, H | 1 |
| Nielsen, K | 1 |
| Ingvar, C | 1 |
| Andersson, TML | 1 |
| Girnita, A | 1 |
| Smedby, KE | 1 |
| Eriksson, H | 1 |
1 other study available for metformin and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
Topics: Adult; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Melanoma; Melanoma, C | 2023 |